BioVie Past Earnings Performance

Past criteria checks 0/6

BioVie has been growing earnings at an average annual rate of 4.8%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

4.8%

Earnings growth rate

37.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-181.7%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

Oct 14

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

Sep 06

BioVie: Four Potential Catalysts Around The Corner

Jun 07

Revenue & Expenses Breakdown

How BioVie makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:BIVI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-27916
30 Jun 240-33923
31 Mar 240-37929
31 Dec 230-43935
30 Sep 230-511135
30 Jun 230-501233
31 Mar 230-491231
31 Dec 220-411223
30 Sep 220-31921
30 Jun 220-261017
31 Mar 220-1507143
31 Dec 210-1457140
30 Sep 210-1437136
30 Jun 210-1845133
31 Mar 210-7152
31 Dec 200-6932
30 Sep 200-5911
30 Jun 200-3411
31 Mar 200-1511
31 Dec 190-1611
30 Sep 190-2311
30 Jun 190-211
31 Mar 190-211
31 Dec 180-211
30 Sep 180-211
30 Jun 180-220
31 Mar 180-220
31 Dec 170-210
30 Sep 170-210
30 Jun 170-110
31 Mar 170-110
31 Dec 160-110
30 Sep 160-100
30 Jun 160000
31 Mar 160000
31 Dec 150000
30 Sep 150000
30 Jun 150000
31 Mar 150000
31 Dec 140000
30 Sep 140000

Quality Earnings: BIVI is currently unprofitable.

Growing Profit Margin: BIVI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIVI is unprofitable, but has reduced losses over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare BIVI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIVI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: BIVI has a negative Return on Equity (-181.72%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies